Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

153 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Early but limited effects of raltegravir intensification on CD4 T cell reconstitution in HIV-infected patients with an immunodiscordant response to antiretroviral therapy.
Negredo E, Massanella M, Puertas MC, Buzón MJ, Puig J, Pérez-Alvárez N, Pérez-Santiago J, Bonjoch A, Moltó J, Jou A, Echeverría P, Llibre JM, Martínez-Picado J, Clotet B, Blanco J. Negredo E, et al. Among authors: jou a. J Antimicrob Chemother. 2013 Oct;68(10):2358-62. doi: 10.1093/jac/dkt183. Epub 2013 May 14. J Antimicrob Chemother. 2013. PMID: 23677919 Free PMC article. Clinical Trial.
Switching from zidovudine to didanosine in patients with symptomatic HIV infection and disease progression. ddI Iberian Study Group.
Gatell JM, González-Lahoz J, Clotet B, Antunes F, Kasparova L, Gil-Aguado A, Saballs P, Santamaria JM, Podzamczer D, Miro JM, Jou A, Verdejo J, Doroana M, Thomis J. Gatell JM, et al. Among authors: jou a. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Jul;12(3):249-58. doi: 10.1097/00042560-199607000-00004. J Acquir Immune Defic Syndr Hum Retrovirol. 1996. PMID: 8673528 Clinical Trial.
Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with </=250/microL CD4 T cells and undetectable plasma virus load.
Arnó A, Ruiz L, Juan M, Jou A, Balagué M, Zayat MK, Marfil S, Martínez-Picado J, Martínez MA, Romeu J, Pujol-Borrell R, Lane C, Clotet B. Arnó A, et al. Among authors: jou a. J Infect Dis. 1999 Jul;180(1):56-60. doi: 10.1086/314831. J Infect Dis. 1999. PMID: 10353861 Clinical Trial.
High-dose saquinavir plus ritonavir: long-term efficacy in HIV-positive protease inhibitor-experienced patients and predictors of virologic response.
Paredes R, Puig T, Arnó A, Negredo E, Balagué M, Bonjoch A, Jou A, Tuldrà A, Tural C, Sirera G, Veny A, Romeu J, Ruiz L, Clotet B. Paredes R, et al. Among authors: jou a. J Acquir Immune Defic Syndr. 1999 Oct 1;22(2):132-8. doi: 10.1097/00126334-199910010-00004. J Acquir Immune Defic Syndr. 1999. PMID: 10843526 Clinical Trial.
Prospective randomized two-Arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy.
Tuldrà A, Fumaz CR, Ferrer MJ, Bayés R, Arnó A, Balagué M, Bonjoch A, Jou A, Negredo E, Paredes R, Ruiz L, Romeu J, Sirera G, Tural C, Burger D, Clotet B. Tuldrà A, et al. Among authors: jou a. J Acquir Immune Defic Syndr. 2000 Nov 1;25(3):221-8. doi: 10.1097/00126334-200011010-00003. J Acquir Immune Defic Syndr. 2000. PMID: 11115952 Clinical Trial.
Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression.
Negredo E, Cruz L, Paredes R, Ruiz L, Fumaz CR, Bonjoch A, Gel S, Tuldrà A, Balagué M, Johnston S, Arnó A, Jou A, Tural C, Sirera G, Romeu J, Clotet B. Negredo E, et al. Among authors: jou a. Clin Infect Dis. 2002 Feb 15;34(4):504-10. doi: 10.1086/324629. Epub 2002 Jan 2. Clin Infect Dis. 2002. PMID: 11797178 Clinical Trial.
Benefit of switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): interim analysis at 3 months of follow-up.
Negredo E, Paredes R, Bonjoch A, Tuldrà A, Fumaz CR, Gel S, Garcés B, Johnston S, Arnó A, Balagué M, Jou A, Tural C, Sirera G, Romeu J, Cruz L, Francia E, Domingo P, Arrizabalaga J, Ruiz I, Arribas JR, Ruiz L, Clotet B. Negredo E, et al. Among authors: jou a. Antivir Ther. 1999;4 Suppl 3:23-8. Antivir Ther. 1999. PMID: 16021868 Clinical Trial.
153 results